Docosatetraenoylethanolamide

Docosatetraenoylethanolamide (DEA) is an endogenous ethanolamide that has been shown to act on the cannabinoid (CB1) receptor.[1] DEA is similar in structure to anandamide (AEA, a recognized endogenous ligand for the CB1 receptor), containing docosatetraenoic acid in place of arachidonic acid. While DEA has been shown to bind to the CB1 receptor with similar potency and efficacy as AEA, its role as a cannabinergic neurotransmitter is not well understood.

Docosatetraenoylethanolamide
Names
IUPAC name
(7Z,10Z,13Z,16Z)-N-(2-hydroxyethyl)docosa-7,10,13,16-tetraenamide
Other names
DEA
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
Properties
C24H41NO2
Molar mass 375.59 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
N verify (what is YN ?)
Infobox references

References

  1. Hanus, L.; Gopher, A.; Almog, S.; et al. (1993). "Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor". J Med Chem. 36 (20): 3032–3034. doi:10.1021/jm00072a026. PMID 8411021.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.